TL;DR
Wegovy (semaglutide 2.4 mg) produced an average of 14.9% body weight loss over 68 weeks in the STEP-1 trial, compared to 2.4% with placebo. One-third of participants lost 20% or more of their starting weight. Below you will find month-by-month timelines, side effect breakdowns, and results from all four STEP trials.
Wegovy was the first GLP-1 receptor agonist approved specifically for chronic weight management, and it changed obesity treatment when it launched. The medication contains semaglutide, the same active ingredient found in Ozempic, but at a higher dose optimized for weight loss.
The clinical trial data behind Wegovy is extensive. The STEP program enrolled thousands of participants and tracked results over more than a year. If you are researching Wegovy before and after outcomes, this data gives you the most reliable picture of what to expect.
How Much Weight Do People Lose on Wegovy?
The STEP-1 trial showed that participants taking Wegovy (semaglutide 2.4 mg) lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. The trial enrolled 1,961 adults and was published in the New England Journal of Medicine. These results made Wegovy one of the most effective non-surgical weight loss interventions available.
For a 220-pound person, 14.9% weight loss translates to roughly 33 pounds. One-third of participants achieved 20% or more loss, which equals 44 pounds or more at that starting weight.
| Trial | Population | Duration | Avg Loss (Wegovy) | Avg Loss (Placebo) | n |
|---|---|---|---|---|---|
| STEP-1 | Obesity, no diabetes | 68 weeks | 14.9% | 2.4% | 1,961 |
| STEP-2 | Obesity + type 2 diabetes | 68 weeks | 9.6% | 3.4% | 1,210 |
| STEP-3 | With behavioral therapy | 68 weeks | 16.0% | 5.7% | 611 |
| STEP-4 | Continuation vs withdrawal | 68 weeks | Continued: additional 7.9% loss | Switch to placebo: ~7% regain | 902 |
STEP-3 is particularly relevant for patients willing to invest in lifestyle changes alongside medication. When Wegovy was combined with intensive behavioral therapy and a brief low-calorie diet phase, participants lost 16.0% of body weight, about 1 percentage point more than the standard protocol.
What Is the Month-by-Month Wegovy Timeline?
Weight loss on Wegovy follows a gradual curve, with the most rapid losses occurring between months 3 and 8 of treatment. The dose escalation takes about 16 to 20 weeks, meaning you do not reach the full therapeutic dose of 2.4 mg until roughly month 4 or 5. Most patients begin seeing visible results around weeks 6 to 8.
For a complete cost breakdown, see our semaglutide pricing comparison.
The slow titration is designed to reduce gastrointestinal side effects, which are the most common complaint during the early weeks of treatment.
| Timeframe | Dose | What to Expect | Estimated Cumulative Loss |
|---|---|---|---|
| Weeks 1 to 4 | 0.25 mg | Minimal weight loss. Body adjusts to medication. Some appetite changes. | 1 to 2% |
| Weeks 5 to 8 | 0.5 mg | Appetite suppression strengthens. Portions decrease. Mild nausea may occur. | 2 to 4% |
| Weeks 9 to 12 | 1.0 mg | Measurable weight loss underway. Clothes fit differently. Cravings diminish. | 4 to 7% |
| Weeks 13 to 16 | 1.7 mg | Rapid loss phase begins. Most side effects stabilize. Energy improves. | 6 to 9% |
| Weeks 17 to 20 | 2.4 mg | Full therapeutic dose reached. Maximum appetite suppression. Steady loss. | 8 to 11% |
| Weeks 21 to 40 | 2.4 mg | Peak weight loss period. Significant visible transformation. Lab markers improve. | 11 to 15% |
| Weeks 41 to 68 | 2.4 mg | Loss slows approaching plateau. Focus on maintenance and body composition. | 14 to 17% |
Individual results vary. Patients with higher starting BMIs often see faster initial losses. Those with type 2 diabetes typically lose weight more slowly, as seen in STEP-2 data.
What Are the Side Effects of Wegovy?
Gastrointestinal side effects are significantly more common with Wegovy than with tirzepatide-based medications. In the STEP-1 trial, nausea was reported by 44% of participants on semaglutide 2.4 mg versus 18% on placebo. These side effects are the primary reason for the gradual dose escalation schedule.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →The good news is that most GI symptoms are worst during the first few weeks at each new dose level and improve as the body adjusts. Only about 7% of participants in STEP-1 discontinued treatment due to side effects.
| Side Effect | Wegovy 2.4 mg | Placebo | Typical Duration |
|---|---|---|---|
| Nausea | 44% | 18% | 2 to 6 weeks per dose step |
| Diarrhea | 30% | 16% | 1 to 3 weeks |
| Vomiting | 24% | 6% | 1 to 2 weeks per dose step |
| Constipation | 24% | 11% | Variable, may persist |
| Abdominal pain | 20% | 11% | 2 to 4 weeks |
| Headache | 14% | 12% | 1 to 2 weeks |
| Fatigue | 11% | 5% | 2 to 4 weeks |
Serious adverse events are uncommon. The FDA label includes warnings about pancreatitis, gallbladder disease, acute kidney injury, and thyroid C-cell tumors (based on rodent studies). Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
How Does Wegovy Compare to Mounjaro?
Mounjaro (tirzepatide) has consistently produced greater weight loss in clinical trials, averaging 20.9% body weight loss at 15 mg versus 14.9% for Wegovy at 2.4 mg. The roughly 6-percentage-point gap is clinically meaningful and reflects the difference between a dual GIP/GLP-1 mechanism and GLP-1 alone.
That said, Wegovy remains an excellent option for many patients. Some people tolerate semaglutide better than tirzepatide. Insurance coverage patterns differ between the two.
And for patients already seeing strong results on Wegovy, there may be no clinical reason to switch.
| Feature | Wegovy (semaglutide 2.4 mg) | Mounjaro (tirzepatide 15 mg) |
|---|---|---|
| Mechanism | GLP-1 only | Dual GIP/GLP-1 |
| Avg weight loss | 14.9% | 20.9% |
| % losing 20%+ | ~33% | 57% |
| Nausea rate | 44% | 24% |
| FDA approved for weight loss | Yes | Yes (as Zepbound) |
| Time on market (weight loss) | Since June 2021 | Since November 2023 |
If cost is your primary concern, compounded versions of both semaglutide and tirzepatide are available at significantly lower prices. Compare GLP-1 options without insurance here.
What Do the STEP Clinical Trials Show?
The STEP program is the foundation of evidence for Wegovy, comprising four major trials that enrolled over 4,500 participants. STEP-1 established the baseline efficacy, while subsequent trials explored performance in diabetic populations, combined with behavioral therapy, and after treatment discontinuation.
STEP-4 is the most important trial for understanding long-term treatment planning. After 20 weeks on semaglutide 2.4 mg, participants were randomized to continue treatment or switch to placebo.
Participants who continued Wegovy lost an additional 7.9% of body weight over the next 48 weeks. Those who switched to placebo regained about two-thirds of their weight loss. The message is clear: sustained treatment produces sustained results.
Stopping the medication typically leads to significant weight regain.
How Do You Get Started on Wegovy?
Wegovy is available by prescription through your primary care physician, an endocrinologist, or a telehealth provider. At FormBlends, we offer physician-supervised GLP-1 treatment programs that include medical evaluation, prescription, medication delivery, and ongoing clinical support.
The brand-name Wegovy pen costs approximately $1,300 per month without insurance. Compounded semaglutide offers the same active ingredient at a significantly lower price point, typically $199 per month through FormBlends. The dosing, titration schedule, and physician oversight are identical.
If you are exploring compounded options, compare compounded semaglutide pricing here.
How to Get the Most from Wegovy Treatment
Patients who combine Wegovy with structured lifestyle changes achieve better outcomes. The STEP-3 trial showed 16.0% average weight loss when semaglutide was paired with intensive behavioral therapy, compared to 14.9% in the standard STEP-1 protocol. Small differences in approach add up over months of treatment.
Protein is the top dietary priority. Target 25 to 30 grams per meal. Reduced appetite makes it easy to undereat protein, which accelerates lean muscle loss.
A simple approach: build every meal around a protein source first, then add vegetables and whole grains.
Resistance training protects against muscle loss during rapid weight loss. Even 2 sessions per week of basic strength exercises makes a measurable difference in body composition. Combined with adequate protein, this strategy shifts the ratio of fat loss to lean mass loss substantially in your favor.
Use the FormBlends weight loss timeline calculator to set personalized monthly goals based on your starting weight and medication.
Frequently Asked Questions
How much weight can you lose on Wegovy?
The STEP-1 trial showed an average weight loss of 14.9% of body weight over 68 weeks on Wegovy (semaglutide 2.4 mg). For a 220-pound person, that translates to roughly 33 pounds. One-third of participants lost 20% or more of their body weight.
How quickly does Wegovy work?
Most patients notice appetite reduction within the first 1 to 2 weeks. Visible weight loss typically appears by weeks 4 to 8. The dose escalation takes about 16 to 20 weeks to reach the full therapeutic dose of 2.4 mg.
What are Wegovy side effects?
The most common side effects are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) in the STEP-1 trial. These tend to be worst during dose escalation and improve over time.
Is Wegovy the same as Ozempic?
Both contain semaglutide, but at different doses and for different indications. Wegovy delivers 2.4 mg weekly and is FDA-approved for weight management. Ozempic delivers up to 2.0 mg weekly and is approved for type 2 diabetes.
The higher Wegovy dose produces greater weight loss.
What happens when you stop Wegovy?
The STEP-4 trial showed that patients who switched from semaglutide to placebo regained approximately 7% of body weight over 48 weeks, losing about two-thirds of the weight loss they had achieved. Ongoing treatment is recommended for sustained results.
Does insurance cover Wegovy?
Coverage varies widely. Some commercial insurance plans cover Wegovy for patients who meet BMI criteria. Medicare does not currently cover weight loss medications.
Many patients use compounded semaglutide as a more affordable alternative. Check our guide on the cheapest semaglutide options for details.
Can Wegovy be used with type 2 diabetes?
Yes. The STEP-2 trial specifically studied semaglutide 2.4 mg in adults with obesity and type 2 diabetes. Participants lost an average of 9.6% of body weight with significant improvements in blood sugar control.
How does Wegovy compare to Mounjaro?
Mounjaro (tirzepatide) has produced greater average weight loss in clinical trials: 20.9% vs 14.9% at their respective highest doses. However, both are highly effective, and individual responses vary. Some patients do better on one medication than the other.